Skip to main content
Premium Trial:

Request an Annual Quote

Clairus Hints at Collaboration with Ivy League Lab in Q4

WASHINGTON, DC, Oct. 3 – Clairus Technologies said that it is set to sign a letter of intent with an Ivy League university in the US to collaborate research on certain genomic-based diagnostic products, a company official said on Wednesday.

Gregory Sullivan, senior vice president of business development and marketing at Clairus, told GenomeWeb that the partnership should be finalized in the current quarter. He spoke outside the Biotechnology Industry Organization Venture Forum meeting here, which runs through Thursday.

The deal centers on technology developed at the university, which was not named, that detects the origin of a variety of inflammatory responses, including those that cause asthma and inflammatory bowel disease, Sullivan said.

Clairus, based in Rockville, Md., links research efforts of its own laboratory with those of academic centers, the government, or industry as a way to fatten resources for tool invention and diagnostic- and drug-discovery.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.